Psychiatr Res Clin Pract
February 11, 2025
Jules Evans, Marc Aixalà, Brian T Anderson et al.
18 citations
Objective: This article outlines recommendations from 30 psychedelic researchers on how to create a better psychedelic safety net. Methods: A survey of 30 psychedelic researchers asked them to identify key critical research gaps around psychedelic harm and safety. Results: The critical research gaps identified by the authors included defining the main types of psychedelic harm, the predictors...
Psychiatric Services
2023
Brian Holoyda
7 citations
Psychedelics have the ability to fundamentally alter the consciousness of individuals who take them and thus pose unique legal risks for psychiatrists interested in incorporating them into their practice. Several issues related to malpractice may be relevant, including absence of standards of care, risk of harm, inappropriate treatment, and the doctrine of respondeat superior. In addition to...
Current Psychiatry
2021
Brian Holoyda
1 citation
M r.P, age 65, has a history of major depressive disorder (MDD), gen- eralized anxiety disorder, and social phobia.Mr. P's personality is high in neuroticism and he has often responded to new situations with feelings of impending doom.For him, fear, anxious rumination, helplessness, and catastrophizing are familiar mental processes.When he was in his 30s, Mr. P had a severe major depressive...
Psychiatric Services
October 14, 2020
Brian Holoyda
10 citations
The past decade has seen a renaissance of research interest into the psychotherapeutic potential of psychedelic compounds. In 2019, Oakland and Denver became the first two jurisdictions in the United States to decriminalize the possession of psychedelic-containing organisms. As research and public policy continue to evolve, it becomes increasingly plausible that psychedelics will become viable...
The journal of the American Academy of Psychiatry and the Law
March 1, 2020
Brian Holoyda
8 citations
Recent years have seen a renaissance of research into the use of psychedelic compounds to address various psychiatric conditions. The study of these substances went dormant in 1970 when the United States government passed the Controlled Substances Act, which categorized lysergic acid diethylamide, commonly known as LSD or acid, as a Schedule I drug. The rise of psychedelics in research settings...